GLP-1R Agonists in Children

Both patients and providers have questions about the latest obesity medications, and pediatric endocrinologist Srinath Sanda, MD, has answers. After revealing the surprising reason GLP-1 RAs are effective, his talk covers strategies to ensure safe use in the pediatric population – despite a lack of specific guidelines. He shows the evidence on semaglutide's effect on BMI in adolescents; discusses realistic concerns, such as weight regain and lean tissue loss; and explains which screening tests should precede writing a prescription. He also offers perspectives on adverse events, ranging from gallstones and pancreatitis to increased thyroid cancer risk. Knowing that some PCPs will remain uncomfortable with initiating the drugs, Sanda describes productive steps they can take while their patients wait to see a specialist. Fun bonus: Learn how Gila monsters played a role in the development of these drugs.

Learning Objectives:

• The physiology of endogenous GLP-1 secretion

• Currently approved medications to treat pediatric obesity

• The data from the STEP-TEENS trial that lead to the approval of semaglutide

• Potential adverse events associated with semaglutide use.